CHARLES RIVER LABORATORIES (CRL) Fundamental Analysis & Valuation

NYSE:CRL • US1598641074

152.66 USD
-16.25 (-9.62%)
At close: Mar 12, 2026
152.66 USD
0 (0%)
After Hours: 3/12/2026, 8:04:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This CRL fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

4

Overall CRL gets a fundamental rating of 4 out of 10. We evaluated CRL against 57 industry peers in the Life Sciences Tools & Services industry. CRL has only an average score on both its financial health and profitability. CRL is valued correctly, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

4

1. CRL Profitability Analysis

1.1 Basic Checks

  • In the past year CRL was profitable.
  • In the past year CRL had a positive cash flow from operations.
  • CRL had positive earnings in 4 of the past 5 years.
  • In the past 5 years CRL always reported a positive cash flow from operatings.
CRL Yearly Net Income VS EBIT VS OCF VS FCFCRL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M 600M

1.2 Ratios

  • CRL has a Return On Assets of -2.02%. This is comparable to the rest of the industry: CRL outperforms 57.89% of its industry peers.
  • CRL has a Return On Equity (-4.56%) which is comparable to the rest of the industry.
  • With a decent Return On Invested Capital value of 6.60%, CRL is doing good in the industry, outperforming 75.44% of the companies in the same industry.
  • CRL had an Average Return On Invested Capital over the past 3 years of 6.85%. This is significantly below the industry average of 11.85%.
Industry RankSector Rank
ROA -2.02%
ROE -4.56%
ROIC 6.6%
ROA(3y)1.3%
ROA(5y)3.17%
ROE(3y)2.98%
ROE(5y)8.14%
ROIC(3y)6.85%
ROIC(5y)7.38%
CRL Yearly ROA, ROE, ROICCRL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5 10 15

1.3 Margins

  • Looking at the Operating Margin, with a value of 12.51%, CRL is in the better half of the industry, outperforming 73.68% of the companies in the same industry.
  • In the last couple of years the Operating Margin of CRL has declined.
  • CRL has a worse Gross Margin (34.98%) than 63.16% of its industry peers.
  • In the last couple of years the Gross Margin of CRL has remained more or less at the same level.
Industry RankSector Rank
OM 12.51%
PM (TTM) N/A
GM 34.98%
OM growth 3Y-8.99%
OM growth 5Y-4.24%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.66%
GM growth 5Y-0.96%
CRL Yearly Profit, Operating, Gross MarginsCRL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 20 30

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. CRL Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so CRL is destroying value.
  • The number of shares outstanding for CRL has been reduced compared to 1 year ago.
  • CRL has less shares outstanding than it did 5 years ago.
  • CRL has a worse debt/assets ratio than last year.
CRL Yearly Shares OutstandingCRL Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M
CRL Yearly Total Debt VS Total AssetsCRL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B

2.2 Solvency

  • CRL has an Altman-Z score of 2.26. This is not the best score and indicates that CRL is in the grey zone with still only limited risk for bankruptcy at the moment.
  • CRL has a Altman-Z score (2.26) which is comparable to the rest of the industry.
  • The Debt to FCF ratio of CRL is 4.13, which is a neutral value as it means it would take CRL, 4.13 years of fcf income to pay off all of its debts.
  • CRL has a Debt to FCF ratio of 4.13. This is in the better half of the industry: CRL outperforms 73.68% of its industry peers.
  • A Debt/Equity ratio of 0.68 indicates that CRL is somewhat dependend on debt financing.
  • CRL has a Debt to Equity ratio of 0.68. This is in the lower half of the industry: CRL underperforms 71.93% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.68
Debt/FCF 4.13
Altman-Z 2.26
ROIC/WACC0.63
WACC10.52%
CRL Yearly LT Debt VS Equity VS FCFCRL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B

2.3 Liquidity

  • CRL has a Current Ratio of 1.29. This is a normal value and indicates that CRL is financially healthy and should not expect problems in meeting its short term obligations.
  • CRL has a worse Current ratio (1.29) than 80.70% of its industry peers.
  • A Quick Ratio of 1.02 indicates that CRL should not have too much problems paying its short term obligations.
  • CRL has a worse Quick ratio (1.02) than 80.70% of its industry peers.
Industry RankSector Rank
Current Ratio 1.29
Quick Ratio 1.02
CRL Yearly Current Assets VS Current LiabilitesCRL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. CRL Growth Analysis

3.1 Past

  • CRL shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -0.39%.
  • The Earnings Per Share has been growing slightly by 4.78% on average over the past years.
  • CRL shows a decrease in Revenue. In the last year, the revenue decreased by -0.85%.
  • The Revenue has been growing slightly by 6.55% on average over the past years.
EPS 1Y (TTM)-0.39%
EPS 3Y-2.61%
EPS 5Y4.78%
EPS Q2Q%-10.15%
Revenue 1Y (TTM)-0.85%
Revenue growth 3Y0.33%
Revenue growth 5Y6.55%
Sales Q2Q%-0.83%

3.2 Future

  • Based on estimates for the next years, CRL will show a quite strong growth in Earnings Per Share. The EPS will grow by 9.31% on average per year.
  • The Revenue is expected to grow by 3.54% on average over the next years.
EPS Next Y8.47%
EPS Next 2Y8.74%
EPS Next 3Y8.89%
EPS Next 5Y9.31%
Revenue Next Year1.31%
Revenue Next 2Y2.13%
Revenue Next 3Y2.87%
Revenue Next 5Y3.54%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
CRL Yearly Revenue VS EstimatesCRL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 1B 2B 3B 4B 5B
CRL Yearly EPS VS EstimatesCRL Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5 10 15 20

More info and screens

Find the best growth stocksShow best growing peers

6

4. CRL Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 14.85, CRL is valued correctly.
  • 92.98% of the companies in the same industry are more expensive than CRL, based on the Price/Earnings ratio.
  • When comparing the Price/Earnings ratio of CRL to the average of the S&P500 Index (25.71), we can say CRL is valued slightly cheaper.
  • The Price/Forward Earnings ratio is 13.69, which indicates a correct valuation of CRL.
  • Based on the Price/Forward Earnings ratio, CRL is valued cheaper than 89.47% of the companies in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 23.82. CRL is valued slightly cheaper when compared to this.
Industry RankSector Rank
PE 14.85
Fwd PE 13.69
CRL Price Earnings VS Forward Price EarningsCRL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, CRL is valued cheaper than 94.74% of the companies in the same industry.
  • 87.72% of the companies in the same industry are more expensive than CRL, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 14.49
EV/EBITDA 10.43
CRL Per share dataCRL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 20 40 60 80

4.3 Compensation for Growth

  • The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
PEG (NY)1.75
PEG (5Y)3.11
EPS Next 2Y8.74%
EPS Next 3Y8.89%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CRL Dividend Analysis

5.1 Amount

  • CRL does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CRL Fundamentals: All Metrics, Ratios and Statistics

CHARLES RIVER LABORATORIES

NYSE:CRL (3/12/2026, 8:04:00 PM)

After market: 152.66 0 (0%)

152.66

-16.25 (-9.62%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-18
Earnings (Next)05-05
Inst Owners110.03%
Inst Owner Change3.95%
Ins Owners0.94%
Ins Owner Change5.84%
Market Cap7.52B
Revenue(TTM)4.02B
Net Income(TTM)-144.34M
Analysts78.26
Price Target206.28 (35.12%)
Short Float %6.07%
Short Ratio3.19
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)1.93%
Min EPS beat(2)0.98%
Max EPS beat(2)2.88%
EPS beat(4)4
Avg EPS beat(4)9.75%
Min EPS beat(4)0.98%
Max EPS beat(4)23.68%
EPS beat(8)8
Avg EPS beat(8)9.14%
EPS beat(12)12
Avg EPS beat(12)7.96%
EPS beat(16)16
Avg EPS beat(16)6.74%
Revenue beat(2)1
Avg Revenue beat(2)0.06%
Min Revenue beat(2)-0.27%
Max Revenue beat(2)0.38%
Revenue beat(4)3
Avg Revenue beat(4)1.83%
Min Revenue beat(4)-0.27%
Max Revenue beat(4)3.74%
Revenue beat(8)6
Avg Revenue beat(8)1.34%
Revenue beat(12)9
Avg Revenue beat(12)1.37%
Revenue beat(16)11
Avg Revenue beat(16)1.18%
PT rev (1m)-6.85%
PT rev (3m)6.76%
EPS NQ rev (1m)-24.41%
EPS NQ rev (3m)-24.74%
EPS NY rev (1m)1.49%
EPS NY rev (3m)1.63%
Revenue NQ rev (1m)-1.59%
Revenue NQ rev (3m)-1.68%
Revenue NY rev (1m)-0.39%
Revenue NY rev (3m)-0.36%
Valuation
Industry RankSector Rank
PE 14.85
Fwd PE 13.69
P/S 1.87
P/FCF 14.49
P/OCF 10.19
P/B 2.37
P/tB 124.46
EV/EBITDA 10.43
EPS(TTM)10.28
EY6.73%
EPS(NY)11.15
Fwd EY7.3%
FCF(TTM)10.53
FCFY6.9%
OCF(TTM)14.98
OCFY9.82%
SpS81.56
BVpS64.28
TBVpS1.23
PEG (NY)1.75
PEG (5Y)3.11
Graham Number121.94
Profitability
Industry RankSector Rank
ROA -2.02%
ROE -4.56%
ROCE 8.35%
ROIC 6.6%
ROICexc 6.84%
ROICexgc 14.71%
OM 12.51%
PM (TTM) N/A
GM 34.98%
FCFM 12.91%
ROA(3y)1.3%
ROA(5y)3.17%
ROE(3y)2.98%
ROE(5y)8.14%
ROIC(3y)6.85%
ROIC(5y)7.38%
ROICexc(3y)7.1%
ROICexc(5y)7.66%
ROICexgc(3y)16.12%
ROICexgc(5y)18.95%
ROCE(3y)8.67%
ROCE(5y)9.34%
ROICexgc growth 3Y-11.32%
ROICexgc growth 5Y-5.63%
ROICexc growth 3Y-6.27%
ROICexc growth 5Y-3.36%
OM growth 3Y-8.99%
OM growth 5Y-4.24%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.66%
GM growth 5Y-0.96%
F-Score5
Asset Turnover0.56
Health
Industry RankSector Rank
Debt/Equity 0.68
Debt/FCF 4.13
Debt/EBITDA 2.36
Cap/Depr 54.34%
Cap/Sales 5.46%
Interest Coverage 4.94
Cash Conversion 81.47%
Profit Quality N/A
Current Ratio 1.29
Quick Ratio 1.02
Altman-Z 2.26
F-Score5
WACC10.52%
ROIC/WACC0.63
Cap/Depr(3y)73.38%
Cap/Depr(5y)82.63%
Cap/Sales(3y)6.31%
Cap/Sales(5y)6.71%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-0.39%
EPS 3Y-2.61%
EPS 5Y4.78%
EPS Q2Q%-10.15%
EPS Next Y8.47%
EPS Next 2Y8.74%
EPS Next 3Y8.89%
EPS Next 5Y9.31%
Revenue 1Y (TTM)-0.85%
Revenue growth 3Y0.33%
Revenue growth 5Y6.55%
Sales Q2Q%-0.83%
Revenue Next Year1.31%
Revenue Next 2Y2.13%
Revenue Next 3Y2.87%
Revenue Next 5Y3.54%
EBIT growth 1Y-8.84%
EBIT growth 3Y-8.7%
EBIT growth 5Y2.04%
EBIT Next Year25.47%
EBIT Next 3Y11.29%
EBIT Next 5Y9.93%
FCF growth 1Y3.37%
FCF growth 3Y20.69%
FCF growth 5Y6.41%
OCF growth 1Y0.42%
OCF growth 3Y5.98%
OCF growth 5Y6.18%

CHARLES RIVER LABORATORIES / CRL FAQ

What is the fundamental rating for CRL stock?

ChartMill assigns a fundamental rating of 4 / 10 to CRL.


What is the valuation status of CHARLES RIVER LABORATORIES (CRL) stock?

ChartMill assigns a valuation rating of 6 / 10 to CHARLES RIVER LABORATORIES (CRL). This can be considered as Fairly Valued.


How profitable is CHARLES RIVER LABORATORIES (CRL) stock?

CHARLES RIVER LABORATORIES (CRL) has a profitability rating of 4 / 10.


Can you provide the expected EPS growth for CRL stock?

The Earnings per Share (EPS) of CHARLES RIVER LABORATORIES (CRL) is expected to grow by 8.47% in the next year.